Tariffazione dell’uso delle infrastrutture stradali da parte dei veicoli pesanti: la valutazione d’impatto di politiche a scala europea

La Direttiva Eurovignetta (1999/62/EC e sue successive modifiche) definisce a livello europeo la politica di tariffazione stradale attraverso la regolazione dell’applicazione di tasse, pedaggi e diritti di utenza ai veicoli commerciali che utilizzano la rete di trasporto trans-europea e altre autostrade. Nonostante la Direttiva si collochi lontano nel tempo, il panorama europeo delle tariffe autostradali è ancora oggi discordante e necessita di essere armonizzato. Quest’articolo illustra i principali risultati di un’analisi ex-post sugli impatti della Direttiva Eurovignetta e descrive la metodologia di valutazione seguita per l’analisi ex-ante d’impatti derivanti da future proposte legislative europee

Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study

Purpose: We examined auxological changes in growth hormone (GH)-treated children in Italy using data from the Italian cohort of the multinational observational Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) of pediatric patients requiring GH treatment. Methods: We studied 711 children (median baseline age 9.6 years). Diagnosis associated with short stature was as determined by the investigator. Height standard deviation score (SDS) was evaluated yearly until final or near-final height (n = 78). Adverse events were assessed in all GH-treated patients. Results: The diagnosis resulting in GH treatment was GH deficiency (GHD) in 85.5 % of patients, followed by Turner syndrome (TS 6.6 %). Median starting GH dose was higher in patients with TS (0.30 mg/kg/week) than patients with GHD (0.23 mg/kg/week). Median (interquartile range) GH treatment duration was 2.6 (0.6\u20133.7) years. Mean (95 % confidence interval) final height SDS gain was 2.00 (1.27\u20132.73) for patients with organic GHD (n = 18) and 1.19 (0.97\u20131.40) for patients with idiopathic GHD (n = 41), but lower for patients with TS, 0.37 ( 120.03 to 0.77, n = 13). Final height SDS was > 122 for 94 % of organic GHD, 88 % of idiopathic GHD and 62 % of TS patients. Mean age at GH start was lower for organic GHD patients, and treatment duration was longer than for other groups, resulting in greater mean final height gain. GH-related adverse events occurred mainly in patients diagnosed with idiopathic GHD. Conclusions: Data from the Italian cohort of GeNeSIS showed auxological changes and safety of GH therapy consistent with results from international surveillance databases

Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study

Background: The National Research Council (CNR) prostate cancer monitoring project in Italy (Pros-IT CNR) is an observational, prospective, ongoing, multicentre study aiming to monitor a sample of Italian males diagnosed as new cases of prostate cancer. The present study aims to present data on the quality of life at time prostate cancer is diagnosed. Methods: One thousand seven hundred five patients were enrolled. Quality of life is evaluated at the time cancer was diagnosed and at subsequent assessments via the Italian version of the University of California Los Angeles-Prostate Cancer Index (UCLA-PCI) and the Short Form Health Survey (SF-12). Results: At diagnosis, lower scores on the physical component of the SF-12 were associated to older ages, obesity and the presence of 3+ moderate/severe comorbidities. Lower scores on the mental component were associated to younger ages, the presence of 3+ moderate/severe comorbidities and a T-score higher than one. Urinary and bowel functions according to UCLA-PCI were generally good. Almost 5% of the sample reported using at least one safety pad daily to control urinary loss; less than 3% reported moderate/severe problems attributable to bowel functions, and sexual function was a moderate/severe problem for 26.7%. Diabetes, 3+ moderate/severe comorbidities, T2 or T3-T4 categories and a Gleason score of eight or more were significantly associated with lower sexual function scores at diagnosis. Conclusions: Data collected by the Pros-IT CNR study have clarified the baseline status of newly diagnosed prostate cancer patients. A comprehensive assessment of quality of life will allow to objectively evaluate outcomes of different profile of care

Public transport accessibility through co-modality: Are interconnectivity indicators good enough?

Improving the accessibility of areas using public transport modes in various combinations (or even in combination with car) is one major goal of the concept of co-modality. For co-modality, the quality of interconnectivity is a major requirement to improve accessibility and indicators exist for measuring accessibility and interconnectivity of nodes. However, in this paper we argue that co-modality is not fully measured by most common indicators. Furthermore, in that qualitative aspects are key features of co modality, indicators do not provide enough information for ex-ante analyses

An Analysis of Potential Solutions for Improving Interconnectivity of Passenger Networks. INTERCONNECT Deliverable 3.1

An Analysis of Potential Solutions for Improving Interconnectivity of Passenger Networks

An Analysis of Potential Solutions for Improving Interconnectivity of Passenger Networks. INTERCONNECT Deliverable 3.1

An Analysis of Potential Solutions for Improving Interconnectivity of Passenger Networks